The latest biotech news

News and Trends 16 May 2018

Swedish Biotech Partners With Novo Nordisk to Advance Stem Cell Therapies for Diabetes

BioLamina has partnered with Novo Nordisk to develop stem cell therapies for diabetes and other conditions using a unique cell culture matrix technology. BioLamina, based in Stockholm, is collaborating with the world-leader in diabetes treatment Novo Nordisk to develop stem cell therapies that use BioLamina’s protein cell culture matrices. BioLamina’s technology could enhance Novo Nordisk’s […]

May 16, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 16 May 2018

Actelion’s Billion-Euro Spin-Off Starts First Phase III Trial in its Pipeline

Idorsia has started the first Phase III study in its pipeline to test the drug in patients with a life-threatening genetic disorder, which could bring the company closer to a market launch and profitability. Swiss biotech Idorsia has started a Phase III trial testing its lead compound in patients with Fabry disease, a life-threatening genetic disorder […]

May 16, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 15 May 2018

Series B Funding Helps Dutch Biotech Fight Graft Versus Host Disease

Xenikos has raised $30M (€25M) in Series B funding to conduct Phase III trials for its treatment for acute graft-versus-host disease, a complication of stem cell transplants. Xenikos has raised a substantial Series B fundraising round to conduct Phase III trials in the US and the EU for T-Guard, its treatment for steroid-resistant acute graft […]

May 15, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 15 May 2018

Swiss Company Raises Ambitious IPO to Fight Antibiotic Resistance

Polyphor has closed an IPO of CHF 165M (€138M) to continue developing a new class of antibiotics against pneumonia, as well as treatments for cystic fibrosis and breast cancer. Polyphor, based in Switzerland, has raised a substantial IPO of CHF 165M (€138M) on the SIX Swiss Exchange, surpassing its initial goal of CHF150M (€127M). The funds will […]

May 15, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 15 May 2018

An Epigenetic Drug for Prostate Cancer Gets $26M to Enter Clinical Trials

CellCentric has raised a private round to fund the development of a first-in-class drug with potential to tackle treatment-resistant prostate cancer. Cambridge-based CellCentric has raised $26M from Morningside Venture Investments. The company plans to use the cash to fund the development of an epigenetic cancer drug up to Phase 2b trials. The drug in question, called CCS1477, […]

May 15, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 May 2018

German Biotech Expands Oncology Deal with Bluebird bio to $1.5Bn

Medigene and bluebird bio are increasing the number of cancer targets against which to develop TCR candidates, raising their already huge deal to a massive $1.5Bn. In September 2016, Medigene and bluebird bio partnered to develop T cell receptor-modified T cells (TCR-Ts) as candidates for cancer immunotherapy treatments. Medigene was offered up to $250M per each of […]

May 14, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 May 2018

Swiss Spin-off Secures Funding for Antibodies to Reach Difficult Targets

Memo Therapeutics has raised CHF 5M (€4,2M) to develop its antibody detection technology, which uses whole antibodies to reach difficult targets. Memo Therapeutics, a spin-off from ETH Zurich, has closed a Series A2 round of CHF 5M (€4,2M). The funding was provided by Redalpine Venture Partners and Zurich Cantonal Bank among other investors and will […]

May 9, 2018 - 1 minutemin - By Alexander Burik

News and Trends 8 May 2018

Scottish Biotech Boosts its CAR-T Pipeline for Cancer and HIV

TC Biopharm has partnered with Scotia Biologics to produce tumor-specific antibodies for a new generation of safer CAR-T therapies against multiple types of tumors as well as viral infections such as HIV. The Scottish biotech TC Biopharm will be working with its new partner Scotia Biologics on the development of CAR-T therapy candidates against neuroblastoma, […]

May 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 May 2018

Bionic Implant to Restore Vision Raises Funding to Complete First Human Trial

Pixium Vision has raised €10.6M by offering new shares on Euronext Paris. The funding will be used to develop its bionic vision device further and bring it closer to a European market authorization. Pixium Vision, based in Paris, has raised €10.6M on Euronext Paris to continue the first clinical study of its PRIMA bionic vision system in […]

May 4, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 3 May 2018

FDA Backs Gene Therapy for Fatal Neurodegenerative Childhood Disease

Orchard Therapeutics has received a fourth Rare Pediatric Disease Designation from the FDA for its gene therapy candidate for metachromatic leukodystrophy. Orchard Therapeutics, based in London, has received a Rare Pediatric Disease Designation form the FDA for its gene therapy OTL-200. The treatment is for patients with metachromatic leukodystrophy (MLD), a fatal genetic disease that causes […]

May 3, 2018 - 1 minutemin - By Alexander Burik

News and Trends 3 May 2018

World’s First Gene Therapy Developer Raises $128M for Hemophilia and Huntington’s

uniQure has raised a substantial public offering on the NASDAQ. The funding could help the Dutch biotech advance two new gene therapies after the withdrawal of its first treatment. Amsterdam-based uniQure has raised an ambitious $128M (€107M) in a public offering at the beginning of next week. The Dutch biotech develops gene therapies for hemophilia and Huntington’s disease, for […]

May 3, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 30 Apr 2018

Record Series B Financing Supports Antibody Cancer Therapy

Crescendo Biologics has raised €57M in in the largest disclosed Series B financing in the European biotech sector this year. The company will use the funds to develop its antibody cancer treatment that activates white blood cells to fight tumors. Crescendo Biologics, based in Cambridge, UK, has raised €57M in the largest disclosed Series B financing for the European […]

April 30, 2018 - 2 minutesmins - By Alexander Burik

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Swedish Biotech Partners With Novo Nordisk to Advance Stem Cell Therapies for Diabetes

Actelion’s Billion-Euro Spin-Off Starts First Phase III Trial in its Pipeline

Series B Funding Helps Dutch Biotech Fight Graft Versus Host Disease

Swiss Company Raises Ambitious IPO to Fight Antibiotic Resistance

An Epigenetic Drug for Prostate Cancer Gets $26M to Enter Clinical Trials

German Biotech Expands Oncology Deal with Bluebird bio to $1.5Bn

Swiss Spin-off Secures Funding for Antibodies to Reach Difficult Targets

Scottish Biotech Boosts its CAR-T Pipeline for Cancer and HIV

Bionic Implant to Restore Vision Raises Funding to Complete First Human Trial

FDA Backs Gene Therapy for Fatal Neurodegenerative Childhood Disease

World’s First Gene Therapy Developer Raises $128M for Hemophilia and Huntington’s

Record Series B Financing Supports Antibody Cancer Therapy

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!